Melphalan, BCNU, B12, and ascorbic acid plus ASCT show promise for patients with metastatic PDAC, according to results from the SHARON trial.
Kenneth H. Yu, MD
Advertisement
Articles by Kenneth H. Yu, MD
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic Cancer
Neoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.
Advertisement
Latest Updated Articles
COUNTERPOINT: Weighing the Risks and Benefits of Neoadjuvant Therapy in Resectable Pancreatic CancerPublished: January 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
4
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
5
